Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

TEANECK, N.J., Oct. 16, 2024 /CNW/ -- Cognizant (NASDAQ:CTSH) today announced significant enhancements to its Cognizant Neuro ® AI platform, aimed at enabling enterprises to rapidly discover, ...

Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Cognizant and Palo Alto Networks are partnering to deliver AI-driven cybersecurity capabilities and services for enterprises ...

Pathway to Cures (P2C) announced their annual fund update meeting on Wednesday, September 11th in Atlanta, Georgia. Pathway to Cures (P2C) is the venture philanthropy fund for the National Bleeding ...

Who is Nirmala Bandrapalli? Nirmala Bandrapalli was born in Hyderabad and came to the US for higher education over 30 years ...

Hillyer, MD, President and CEO of NYBCe, and General Partner and Manager of NYBC Ventures. “With a $50 million commitment, we’ve deployed capital across 15 companies that are delivering breakthrough ...

"It is an exciting time at Adverum as we progress toward the initiation of Ixo-vec's pivotal program in the first half of 2025,” stated Laurent Fischer, M.D., president and chief executive officer of ...

Gilead Sciences’ already dominant position in HIV ... twice-yearly lenacapavir for PrEP could help address the stigma and discrimination some people may face when taking or storing oral PrEP ...

Interest in clinical trials is high among members of the LGBTQ community and people of color, though participation rates are ...